Bafna Pharmaceuticals Ltd vs Gujarat Terce Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 10, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 176.95 as of 09 Jun 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 yearsThe P/E Ratio of Gujarat Terce Laboratories Ltd changed from 22.2 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 yearsThe Market Cap of Gujarat Terce Laboratories Ltd changed from ₹ 5.16 crore on March 2021 to ₹ 45.37 crore on March 2025 . This represents a CAGR of 54.46% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 44 crore as compare to the Dec '25 revenue of ₹ 39.51 crore. This represent the growth of 11.36% The revenue of Gujarat Terce Laboratories Ltd for the Mar '26 is ₹ 11.48 crore as compare to the Dec '25 revenue of ₹ 12.42 crore. This represent the decline of -7.57% The ebitda of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 5.31 crore as compare to the Dec '25 ebitda of ₹ 4.27 crore. This represent the growth of 24.36% The ebitda of Gujarat Terce Laboratories Ltd for the Mar '26 is ₹ 0.36 crore as compare to the Dec '25 ebitda of ₹ 1.26 crore. This represent the decline of -71.43% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 2.75 crore over 8 quarters. This represents a CAGR of NaN% The net profit of Gujarat Terce Laboratories Ltd changed from ₹ -0.08 crore to ₹ 0.1 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Gujarat Terce Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Gujarat Terce Laboratories Ltd

Gujarat Terce Laboratories Limited, incorporated in 1985, is a trusted manufacturer of high quality medication at affordable rates for the common man.
Company specialise in producing oral solid dosages, including tablets and capsules, that address various therapeutic needs. Headquartered in Ahmedabad, Gujarat, Terce offers an extensive portfolio featuring over 125 products and more than 64 well-established brands. By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing.
In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange.
In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat.
As India heralded new leaps in the pharma sector to become a global force to reckon with by 2005, the Company closely followed the narrative with ferocious growth expanding presence in the domestic and international market.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Gujarat Terce Laboratories Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 418 Cr while Market cap of Gujarat Terce Laboratories Ltd is 27 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd?

As of June 10, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹176.95. On the other hand, Gujarat Terce Laboratories Ltd stock price is INR ₹34.99.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Gujarat Terce Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.